Enveda's Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV
Envedaは、中等症から重症のアトピー性皮膚炎を対象としたENV-294の第1b相試験の良好な結果がAAD Innovation Academyで発表されたと述べた。追加の詳細はEADVで共有する予定。